AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12107606 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg BDP as eight inhalations from the 50‐microg/actuation strength
Number of subjects: 30
Study 12107606 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg BDP as four inhalations from the 100‐microg/actuation strength
Number of subjects: 30
Study 12107606 — intervention group
Group type: EXPERIMENTAL
Intervention: 50‐microg/actuation strength
Number of subjects: 30
Study 12107606 — intervention group
Group type: EXPERIMENTAL
Intervention: 100‐microg/actuation strength
Number of subjects: 30
Study 10191374 — intervention group
Group type: EXPERIMENTAL
Intervention: FHL and FDL transfer to the os calcis (group II)
Number of subjects: 55
Study 10191374 — intervention group
Group type: COMPARATOR
Intervention: SPLATT, Achilles tendon lengthening, and toe flexor release (group I)
Number of subjects: 55
Study 8703667 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-65021 (5 mg)
Number of subjects: 8
Study 8703667 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-65021 (10 mg)
Number of subjects: 8
Study 8703667 — intervention group
Group type: EXPERIMENTAL
Intervention: HN-65021 (100 mg)
Number of subjects: 8
Study 8703667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1881694 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefatrizine
Number of subjects: 40
Study 1881694 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 40
Study 7044464 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular Dexon sutures
Number of subjects: 104
Study 7044464 — intervention group
Group type: COMPARATOR
Intervention: Interrupted non-absorbable skin sutures
Number of subjects: 104
Study 30644767 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (CBT)
Number of subjects: 71
Study 30644767 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation plus relaxation training (PRT)
Number of subjects: 71
Study 30644767 — intervention group
Group type: COMPARATOR
Intervention: Exposure-based cognitive behavior therapy (CBT) and Psychoeducation plus relaxation training (PRT)
Number of subjects: 71
Study 30644767 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth distress ratings
Number of subjects: 71
Study 28887116 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Peripheral Iridotomy (LPI)
Number of subjects: 181
Study 28887116 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors
Number of subjects: 181
Study 27578839 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional T-stent strategy
Number of subjects: 200
Study 27578839 — intervention group
Group type: COMPARATOR
Intervention: Dual stent culotte technique
Number of subjects: 200
Study 24476484 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise before aerobic exercise (AR)
Number of subjects: 0
Study 24476484 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise after aerobic exercise (RA)
Number of subjects: 0
Study 23014835 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip replacement (n = 43)
Number of subjects: 100
Study 23014835 — intervention group
Group type: COMPARATOR
Intervention: Internal fixation (n = 57)
Number of subjects: 100
Study 19583078 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.75% of inspired concentration (GI n = 15)
Number of subjects: 30
Study 19583078 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil continuous infusion of 0.4 microg x kg(‐1) x mn(‐1) (GR n = 15)
Number of subjects: 30
Study 19583078 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 30
Study 19583078 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 30
Study 17109440 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional microscopy
Number of subjects: 96
Study 17109440 — intervention group
Group type: COMPARATOR
Intervention: Virtual microscopy
Number of subjects: 96
Study 15172856 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation training on shoulder dystocia management
Number of subjects: 0
Study 15172856 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific training
Number of subjects: 0
Study 12512790 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 121
Study 12512790 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture using the Park Sham Device
Number of subjects: 121
Study 12512790 — intervention group
Group type: EXPERIMENTAL
Intervention: Judgements by acupuncture experts
Number of subjects: 121
Study 9794988 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine assessment via real-time audiovisual transmission
Number of subjects: 15
Study 9794988 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-person assessment
Number of subjects: 15
Study 7658530 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Indiana pouch procedure in elderly patients
Number of subjects: 25
Study 7658530 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger patients under 75 years)
Number of subjects: 25
Study 2693996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam (800-mg tablets), given twice daily for 12 weeks
Number of subjects: 289
Study 2693996 — intervention group
Group type: COMPARATOR
Intervention: Placebo, given twice daily for 12 weeks
Number of subjects: 289
Study 2693996 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 289
Study 2693996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 38179 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfasalazine and prednisone
Number of subjects: 89
Study 38179 — intervention group
Group type: COMPARATOR
Intervention: prednisone and placebo
Number of subjects: 89
Study 31541242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir 75 mg twice daily for 5 days
Number of subjects: 449
Study 31541242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 31541242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 449
Study 30659024 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg orally, once daily)
Number of subjects: 556
Study 30659024 — intervention group
Group type: COMPARATOR
Intervention: SoC EGFR-TKI (gefitinib 250 mg or erlotinib 150 mg, orally, once daily)
Number of subjects: 556
Study 28753958 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP+Fe (12.5 mg iron)
Number of subjects: 33
Study 28753958 — intervention group
Group type: EXPERIMENTAL
Intervention: MNP-Fe (no iron)
Number of subjects: 33
Study 28753958 — intervention group
Group type: COMPARATOR
Intervention: CONTROL (placebo)
Number of subjects: 33
Study 26444853 — intervention group
Group type: EXPERIMENTAL
Intervention: Facemask ventilation after neuromuscular blockade (NMB)
Number of subjects: 210
Study 24146101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal EGD (TN-EGD)
Number of subjects: 301
Study 24146101 — intervention group
Group type: COMPARATOR
Intervention: Transoral EGD (TO-EGD)
Number of subjects: 301
Study 24146101 — intervention group
Group type: COMPARATOR
Intervention: Both procedures (TN-EGD and TO-EGD)
Number of subjects: 301
Study 22344561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (160 IU) administered postprandially after lunch
Number of subjects: 2
Study 22344561 — intervention group
Group type: COMPARATOR
Intervention: Intranasal insulin (160 IU) administered in the fasted state
Number of subjects: 2
Study 22344561 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle) administered postprandially after lunch
Number of subjects: 2
Study 19144677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with irinotecan, fluorouracil, and leucovorin (IFL)
Number of subjects: 230
Study 17589693 — intervention group
Group type: EXPERIMENTAL
Intervention: 1M tacrolimus (FK 506)
Number of subjects: 14
Study 15212189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (ISDN)
Number of subjects: 25
Study 15212189 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5-isosorbide mononitrate (5-ISMN)
Number of subjects: 25
Study 15212189 — intervention group
Group type: COMPARATOR
Intervention: Both ISDN and 5-ISMN
Number of subjects: 25
Study 11467638 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 (8 microg/kg)
Number of subjects: 200
Study 11467638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 9743398 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 147
Study 9743398 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with sufentanil 0.5 microg/ml
Number of subjects: 147
Study 9743398 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with sufentanil 1 microg/ml
Number of subjects: 147
Study 9743398 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine with sufentanil 1.5 microg/ml
Number of subjects: 147
Study 7915040 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to their own audiotaped voice describing anxiogenic thoughts (exposure)
Number of subjects: 12
Study 7915040 — intervention group
Group type: COMPARATOR
Intervention: Reading neutral prose or poetry (control)
Number of subjects: 12
Study 7915040 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure only involved anxiogenic thoughts (clinical audit)
Number of subjects: 12
Study 3200595 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instructions plus a pain warning (relevant anxiety condition)
Number of subjects: 0
Study 3200595 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard instructions plus a warning about a stressful interview (irrelevant anxiety condition)
Number of subjects: 0
Study 3200595 — intervention group
Group type: COMPARATOR
Intervention: Standard instructions (control group)
Number of subjects: 0
Study 30965213 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amoxicillin/clavulanic acid from day 29 after the start of treatment until 14 days after completion of chemoradiotherapy
Number of subjects: 106
Study 30965213 — intervention group
Group type: COMPARATOR
Intervention: Standard care without prophylaxis
Number of subjects: 106
Study 30965213 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amoxicillin/clavulanic acid
Number of subjects: 106
Study 28241185 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance intervention delivered primarily by telephone, addressing satisfaction with outcomes, relapse-prevention planning, self-monitoring, and social support.
Number of subjects: 222
Study 28241185 — intervention group
Group type: COMPARATOR
Intervention: Usual care with no contact except for study measurements.
Number of subjects: 222
Study 28241185 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance intervention
Number of subjects: 222
Study 28241185 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study 24916838 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) insulin (duration 48 h)
Number of subjects: 65
Study 24916838 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (SQ) insulin
Number of subjects: 65
Study 22962026 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal information
Number of subjects: 90
Study 22962026 — intervention group
Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 90
Study 22962026 — intervention group
Group type: EXPERIMENTAL
Intervention: Video
Number of subjects: 90
Study 20970238 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Ten Group Classification System (TGCS)
Number of subjects: 0
Study 20970238 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of TGCS interventions
Number of subjects: 0
Study 20970238 — intervention group
Group type: COMPARATOR
Intervention: Baseline period (before TGCS implementation)
Number of subjects: 0
Study 20970238 — intervention group
Group type: EXPERIMENTAL
Intervention: Asphyxia rate
Number of subjects: 0
Study 18425015 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ability to walk
Number of subjects: 78
Study 18425015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological vertebral compression fracture at presentation
Number of subjects: 78
Study 18425015 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative radiation therapy (for patients unable to walk at surgery)
Number of subjects: 78
Study 18425015 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms present for less than 48 hours
Number of subjects: 78
Study 18425015 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 78
Study 16511728 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 0
Study 16511728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14662277 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 440
Study 14662277 — intervention group
Group type: COMPARATOR
Intervention: Nonreamed intramedullary nailing
Number of subjects: 440
Study 10710067 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental Diet (ED)
Number of subjects: 21
Study 10710067 — intervention group
Group type: COMPARATOR
Intervention: Polymeric Diet (PD)
Number of subjects: 21
Study 9221009 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry analysis of lymphocytic infiltrate
Number of subjects: 10
Study 9221009 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunophenotypic analysis of B and T lymphocytes
Number of subjects: 10
Study 8241527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (300 mg nocte)
Number of subjects: 20
Study 8241527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg nocte)
Number of subjects: 20
Study 8241527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and Ebrotidine (both treatments)
Number of subjects: 20
Study 3531860 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b (1 X 10(6) IU) injected into warts three times weekly for three weeks
Number of subjects: 257
Study 3531860 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected into warts three times weekly for three weeks
Number of subjects: 257
Study 3531860 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b
Number of subjects: 257
Study 3531860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 29775491 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care via a mobile app (in addition to routine care)
Number of subjects: 203
Study 29775491 — intervention group
Group type: COMPARATOR
Intervention: Routine discharge care
Number of subjects: 203
Study 26043186 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg twice daily
Number of subjects: 24
Study 26043186 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 24
Study 26043186 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 200 mg once daily
Number of subjects: 24
Study 24299929 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin 2 g
Number of subjects: 400
Study 24299929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 22261740 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Telehealth monitoring with a pendant alarm (up to 12 or 24 weeks)
Number of subjects: 43
Study 22261740 — intervention group
Group type: COMPARATOR
Intervention: Control group (participants with a pendant alarm not from the study service provider or assessed as not needing a pendant alarm)
Number of subjects: 43
Study 20042439 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of prewarming with a carbon fiber total body cover at 42 degrees C
Number of subjects: 27
Study 20042439 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes of preoperative forced-air warming at 42 degrees C
Number of subjects: 27
Study 20042439 — intervention group
Group type: COMPARATOR
Intervention: No prewarming (control group)
Number of subjects: 27
Study 18339977 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine plus insulin lispro
Number of subjects: 56
Study 18339977 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin plus unmodified human insulin
Number of subjects: 56
Study 16492297 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker with sleep rate (SR) function ON
Number of subjects: 22
Study 16492297 — intervention group
Group type: COMPARATOR
Intervention: Pacemaker with sleep rate (SR) function OFF
Number of subjects: 22
Study 13679741 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic free patellar tendon-bone autograft reconstruction of the anterior cruciate ligament (Group 1, 50 patients)
Number of subjects: 100
Study 13679741 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic free patellar tendon-bone autograft reconstruction with lateral extra-articular plasty using the quadriceps tendon (Group 2, 50 patients)
Number of subjects: 100
Study 13679741 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 100
Study 10856869 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG with CPB
Number of subjects: 30
Study 10856869 — intervention group
Group type: COMPARATOR
Intervention: CABG without CPB
Number of subjects: 30
Study 9127850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial tubercle elevation
Number of subjects: 15
Study 1555991 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hyperthermia with radiation therapy (5000‐5040 cGy at 180‐200 cGy per fraction, hyperthermia delivered 30‐60 minutes after radiation for 60 minutes)
Number of subjects: 45
Study 1555991 — intervention group
Group type: COMPARATOR
Intervention: One hyperthermia treatment per week for a total of five treatments
Number of subjects: 45
Study 1555991 — intervention group
Group type: COMPARATOR
Intervention: Two hyperthermia treatments per week for a total of ten treatments
Number of subjects: 45
Study 4003284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) nifedipine (0.1, 0.2 and 0.4 microgram/kg/min over 10 minutes each)
Number of subjects: 9
Study 4003284 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic oral nifedipine (60 mg/day) in combination with atenolol
Number of subjects: 9
Study 4003284 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (100 to 200 mg/day)
Number of subjects: 9
Study 30921737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched CO2 (800 ± 40 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Number of subjects: 0
Study 30921737 — intervention group
Group type: COMPARATOR
Intervention: Ambient CO2 (400 μmol mol-1) under salt stress (80 mmol L-1 NaCl)
Number of subjects: 0
Study 30921737 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched CO2 (800 ± 40 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Number of subjects: 0
Study 30921737 — intervention group
Group type: COMPARATOR
Intervention: Ambient CO2 (400 μmol mol-1) under no salt stress (0 mmol L-1 NaCl)
Number of subjects: 0
Study 28829665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 64
Study 28829665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 64
Study 26251926 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 27
Study 24215850 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg buccal misoprostol
Number of subjects: 85
Study 24215850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 22372394 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led hepatitis programs of different intensity
Number of subjects: 297
Study 22372394 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (≥40), having a partner, and chronic homelessness
Number of subjects: 297
Study 22372394 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger homeless persons and homeless males at risk for HBV
Number of subjects: 297
Study 22372394 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to achieve HBV vaccination completion rates
Number of subjects: 297
Study 19427257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rubber pillow
Number of subjects: 106
Study 19427257 — intervention group
Group type: COMPARATOR
Intervention: Subjects' own pillow
Number of subjects: 106
Study 19427257 — intervention group
Group type: COMPARATOR
Intervention: Foam contour pillow
Number of subjects: 106
Study 19427257 — intervention group
Group type: COMPARATOR
Intervention: Feather pillows
Number of subjects: 106
Study 17982603 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of table sugar (Kandisin)
Number of subjects: 16
Study 17982603 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial sweetener
Number of subjects: 16
Study 17982603 — intervention group
Group type: COMPARATOR
Intervention: Control group (sweetener free)
Number of subjects: 16
Study 15077099 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of reduced-dose reteplase and abciximab combination therapy
Number of subjects: 3000
Study 15077099 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab alone followed by PCI
Number of subjects: 3000
Study 15077099 — intervention group
Group type: COMPARATOR
Intervention: Abciximab alone administered just before PCI
Number of subjects: 3000
Study 15077099 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated PCI treatments (reteplase/abciximab combination therapy or abciximab alone)
Number of subjects: 3000
Study 11707788 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microg/kg clonidine
Number of subjects: 45
Study 11707788 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg ketamine
Number of subjects: 45
Study 11707788 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 45
Study 9566121 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit technology for testimony
Number of subjects: 2
Study 9566121 — intervention group
Group type: COMPARATOR
Intervention: Live testimony in open court
Number of subjects: 2
Study 9566121 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-circuit technology
Number of subjects: 2
Study 9566121 — intervention group
Group type: EXPERIMENTAL
Intervention: Jurors' impressions based on perceived confidence and consistency
Number of subjects: 2
Study 7914235 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated IFN alpha (i-IFN alpha) with immunomodulator P40 and HIV-1 antigens (groups B and C)
Number of subjects: 22